12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xalkori crizotinib: Interim Phase II data

Interim data from 255 evaluable patients with ALK-positive NSCLC who have progressed after receiving >=1 chemotherapy in the open-label, international Phase II PROFILE 1005 trial showed that twice-daily 250 mg Xalkori given in 3-week cycles led to an ORR of 53%, a 12-week DCR of 85% and a median duration of response of 43 weeks. Median PFS was 8.5 months. In 439 patients...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >